Compare BioNano Genomics Inc (BNGO) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Prospect Capital Corporation — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while Prospect Capital Corporation trades at $2.28 (market cap $1.14B). The key difference: Prospect Capital Corporation is far larger — about 86.4× BioNano Genomics Inc's market cap, and Prospect Capital Corporation pays a 22.03% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | PSEC | |
|---|---|---|
Market Cap | $13.20M | $1.14B |
Sector | Health | Financials |
52-Week High | $4.92 | $3.47 |
52-Week Low | $1.09 | $2.15 |
Enterprise Value | $15.81M | — |
Dividend Yield | — | 22.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
PSEC trades at $2.25, down 0.44% recently, with a bearish technical signal and neutral oscillators. The company shows mixed fundamentals with a low P/B of 0.39 and consistent earnings beats in recent quarters, but negative revenue of -$407M and net income margin of -495.94% for 2025 highlight financial stress. Recent news includes a new investment in ShipOffers and ongoing dividend payments, though sentiment is cautious amid a deep discount to NAV.
The outlook remains challenging due to persistent negative revenue and high yield risks, but the valuation discount and earnings beats offer potential for value investors. Key risks include further NAV erosion and dividend sustainability, while institutional sentiment is divided with 25% buy ratings against 55% hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
